Journal of Thrombosis and Thrombolysis

, Volume 46, Issue 1, pp 12–15 | Cite as

Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients

  • Maren Hieber
  • Heiko Hollasch
  • Dorothee Heck
  • Mirjam Mächtel
  • Ulrich Geisen
  • Wolf-Dirk Niesen
  • Jochen Brich
  • Andreas Harloff


Dabigatran is a direct thrombin inhibitor and a non-vitamin-K-antagonizing oral anticoagulant, approved for the prevention of stroke and systemic embolization in atrial fibrillation. Idarucizumab is a humanized monoclonal antibody that was recently approved for antagonizing the anticoagulant effects of dabigatran. Here, we report the use of idarucizumab in four acute stroke patients treated with dabigatran in order to enable intravenous thrombolysis in three patients and emergent trepanation in one patient with space occupying subdural hematoma. Since experience on the optimal management of acute stroke patients under medication with dabigatran and on the use of idarucizumab is currently limited, we propose an approach for laboratory testing and fast administration of intravenous thrombolysis and neurosurgery based on our experience.


Stroke Thrombolysis Intracranial hemorrhage Dabigatran Idarucizumab Antidote 


Compliance with ethical standards

Conflict of interest

Dr. Jochen Brich has received speaker honoraria from Boehringer-Ingelheim und Daiichi Sankyo and travel support from Boehringer-Ingelheim. Prof. Dr. Andreas Harloff has received speaker honoraria from Bayer, Pfizer, Bristol-Myers-Squibb and Boehringer-Ingelheim and participated in a round table meeting organized by Bayer, and the other authors declare that they have no conflict of interest.

Statement of human rights

For this type of study formal consent is not required.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Connolly SJ, Ezekowitz MD, Yusuf S, RE-LY Steering Committee and Investigators et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151. CrossRefPubMedGoogle Scholar
  2. 2.
    Purrucker JC, Steiner T (2017) Management of acute stroke in patients on oral anticoagulants. Curr Opin Neurol 30:1–7. CrossRefPubMedGoogle Scholar
  3. 3.
    van Ryn J, Stangier J, Haertter S et al (2010) Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127. CrossRefPubMedGoogle Scholar
  4. 4.
    Pollack CV, Reilly PA, van Ryn J et al (2017) Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med 377:431–441. CrossRefPubMedGoogle Scholar
  5. 5.
    Diener HC, Bernstein R, Butcher K et al (2017) Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: expert opinion. Int J Stroke. 12:9–12. CrossRefPubMedGoogle Scholar
  6. 6.
    Kermer P, Eschenfelder CC, Diener HC et al (2017) Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—a national case collection. Int J Stroke 12:383–391. CrossRefPubMedGoogle Scholar
  7. 7.
    Tummala R, Kavtaradze A, Gupta A, Ghosh RK (2016) Specific antidotes against direct oral anticoagulants: a comprehensive review of clinical trials data. Int J Cardiol 214:292–298. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Neurology and Clinical Neurophysiology, Medical CenterUniversity of FreiburgFreiburgGermany
  2. 2.Institute of Clinical Chemistry and Laboratory Medicine, Medical CenterUniversity of FreiburgFreiburgGermany
  3. 3.Faculty of MedicineUniversity of FreiburgFreiburgGermany

Personalised recommendations